JP2019530713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530713A5 JP2019530713A5 JP2019519669A JP2019519669A JP2019530713A5 JP 2019530713 A5 JP2019530713 A5 JP 2019530713A5 JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019530713 A5 JP2019530713 A5 JP 2019530713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- day
- administration
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 20
- 208000017169 kidney disease Diseases 0.000 claims description 16
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 14
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000001434 glomerular Effects 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022113880A JP2022141802A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2022113881A JP2022137245A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2024225044A JP2025060754A (ja) | 2016-10-13 | 2024-12-20 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407860P | 2016-10-13 | 2016-10-13 | |
| US62/407,860 | 2016-10-13 | ||
| US201662423079P | 2016-11-16 | 2016-11-16 | |
| US62/423,079 | 2016-11-16 | ||
| PCT/US2017/056538 WO2018071784A1 (en) | 2016-10-13 | 2017-10-13 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113880A Division JP2022141802A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2022113881A Division JP2022137245A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019530713A JP2019530713A (ja) | 2019-10-24 |
| JP2019530713A5 true JP2019530713A5 (OSRAM) | 2020-11-19 |
Family
ID=60191503
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519669A Withdrawn JP2019530713A (ja) | 2016-10-13 | 2017-10-13 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2022113881A Pending JP2022137245A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2022113880A Pending JP2022141802A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2024225044A Pending JP2025060754A (ja) | 2016-10-13 | 2024-12-20 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113881A Pending JP2022137245A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2022113880A Pending JP2022141802A (ja) | 2016-10-13 | 2022-07-15 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| JP2024225044A Pending JP2025060754A (ja) | 2016-10-13 | 2024-12-20 | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20190262317A1 (OSRAM) |
| EP (1) | EP3525784A1 (OSRAM) |
| JP (4) | JP2019530713A (OSRAM) |
| KR (4) | KR20190077348A (OSRAM) |
| CN (5) | CN114788823A (OSRAM) |
| AU (3) | AU2017341825B2 (OSRAM) |
| BR (1) | BR112019007576A2 (OSRAM) |
| CA (1) | CA3039819A1 (OSRAM) |
| MA (1) | MA46524A (OSRAM) |
| WO (1) | WO2018071784A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7524167B2 (ja) * | 2018-10-04 | 2024-07-29 | トラビア セラピューティクス， インコーポレイテッド | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
| CN114126712A (zh) * | 2018-12-21 | 2022-03-01 | 特拉维尔治疗公司 | 无定形司巴森坦（sparsentan）组合物 |
| US20220304979A1 (en) * | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| IL293921A (en) | 2019-12-17 | 2022-08-01 | Chinook Therapeutics Inc | Methods for treating iga kidney disease with atresantan |
| JP2023521169A (ja) * | 2020-04-10 | 2023-05-23 | チヌーク セラピューティクス，インコーポレイテッド | 糖尿病性腎疾患の処置方法 |
| WO2022246200A1 (en) | 2021-05-21 | 2022-11-24 | Travere Therapeutics, Inc. | Methods of treating kidney diseases or disorders |
| KR20240051999A (ko) | 2021-08-26 | 2024-04-22 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도 |
| AR128112A1 (es) * | 2021-12-28 | 2024-03-27 | Alchemedicine Inc | Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| WO2024249509A1 (en) | 2023-05-31 | 2024-12-05 | Travere Therapeutics, Inc. | Sparsentan for use in a method of treating iga-mediated diseases |
| WO2025064688A1 (en) | 2023-09-20 | 2025-03-27 | Travere Therapeutics, Inc. | Sparsentan for treating immunoglobulin a nephropathy (igan) |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| EP1237888B1 (en) | 1999-12-15 | 2006-09-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| EP2413930A4 (en) * | 2009-03-31 | 2012-09-26 | Ligand Pharm Inc | ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY |
| WO2010135350A2 (en) | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| US9719981B2 (en) * | 2012-08-17 | 2017-08-01 | Father Flanagan's Boys' Home | RAC1 inhibitors for the treatment of alport glomerular disease |
| LT3126330T (lt) * | 2014-04-04 | 2019-04-25 | Pfizer Inc. | Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių |
| JP7524167B2 (ja) | 2018-10-04 | 2024-07-29 | トラビア セラピューティクス， インコーポレイテッド | Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物 |
-
2017
- 2017-10-13 CN CN202210441043.8A patent/CN114788823A/zh active Pending
- 2017-10-13 BR BR112019007576A patent/BR112019007576A2/pt not_active Application Discontinuation
- 2017-10-13 EP EP17791821.6A patent/EP3525784A1/en active Pending
- 2017-10-13 CA CA3039819A patent/CA3039819A1/en active Pending
- 2017-10-13 KR KR1020197011413A patent/KR20190077348A/ko not_active Ceased
- 2017-10-13 AU AU2017341825A patent/AU2017341825B2/en active Active
- 2017-10-13 KR KR1020227032048A patent/KR102528435B1/ko active Active
- 2017-10-13 CN CN201780076280.6A patent/CN110049764A/zh active Pending
- 2017-10-13 JP JP2019519669A patent/JP2019530713A/ja not_active Withdrawn
- 2017-10-13 KR KR1020237014470A patent/KR20230066644A/ko not_active Ceased
- 2017-10-13 KR KR1020247036666A patent/KR20240162167A/ko active Pending
- 2017-10-13 CN CN202311093985.2A patent/CN117085013A/zh active Pending
- 2017-10-13 CN CN202311094233.8A patent/CN117017985A/zh active Pending
- 2017-10-13 MA MA046524A patent/MA46524A/fr unknown
- 2017-10-13 WO PCT/US2017/056538 patent/WO2018071784A1/en not_active Ceased
- 2017-10-13 CN CN202311092711.1A patent/CN116983302A/zh active Pending
- 2017-10-13 US US16/340,848 patent/US20190262317A1/en not_active Abandoned
-
2020
- 2020-05-22 US US16/882,206 patent/US10864197B2/en active Active
- 2020-11-12 US US17/096,637 patent/US20210196688A1/en not_active Abandoned
-
2022
- 2022-07-15 JP JP2022113881A patent/JP2022137245A/ja active Pending
- 2022-07-15 JP JP2022113880A patent/JP2022141802A/ja active Pending
-
2023
- 2023-08-22 AU AU2023219839A patent/AU2023219839B2/en active Active
-
2024
- 2024-12-20 JP JP2024225044A patent/JP2025060754A/ja active Pending
-
2025
- 2025-06-27 US US19/253,088 patent/US20250325522A1/en active Pending
- 2025-06-27 US US19/253,120 patent/US20250325523A1/en active Pending
- 2025-11-21 AU AU2025271121A patent/AU2025271121A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530713A5 (OSRAM) | ||
| JP2022028813A (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| JP2017537105A5 (OSRAM) | ||
| JP2013501731A5 (OSRAM) | ||
| JP2016516066A5 (OSRAM) | ||
| JP2014114288A5 (OSRAM) | ||
| JP2016514132A5 (OSRAM) | ||
| JP2016185995A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2016516016A5 (OSRAM) | ||
| JP2015525798A5 (OSRAM) | ||
| Freyne | A case report of immunosuppressant medication‒associated polyarticular tophaceous gout successfully treated using the polyethylene glycol‒conjugated uricase enzyme pegloticase | |
| Kim et al. | Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: an open-label extension study | |
| JP2015172060A5 (OSRAM) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JPWO2020092107A5 (OSRAM) | ||
| JP2019533660A5 (OSRAM) | ||
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2020517671A5 (OSRAM) | ||
| JP2019507786A5 (OSRAM) | ||
| JP2016512247A5 (OSRAM) | ||
| JP2018506533A5 (OSRAM) | ||
| JP2009538916A5 (OSRAM) | ||
| JP2018505901A5 (OSRAM) | ||
| JP2005529152A5 (OSRAM) |